print this page
 

Tashanna Myers, MD

 
Obstetrics-Gynecology Department   Image  
Gynecologic Oncology Division
  • Assistant Professor of Obstetrics-Gynecology, Tufts University School of Medicine
Address
759 Chestnut Street
Springfield, MA 01199
413.794.5542
Tashanna.Myers@baystatehealth.org
 
Education
  • Gynecologic Oncology Fellowship
    University of Oklahoma
    Norman, OK
  • Obstetrics and Gynecology Residency
    Temple University Hospital
    Philadelphia, PA
  • Temple University School of Medicine
    Philadelphia, PA

 

 
Publications
  • Myers T, Chengedza S, Lightfoot S, Pan Y, Dedmond D, Cole L, Tang Y, Benbrook DM. Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Investigational New Drugs 2009; 27(4):304-318.

  • Landrum LM, Moore KN, Myers TK, Lanneau GS, Walker JL, Gold MA.  “Stage IVb endometrial cancer:  Does applying an ovarian cancer treatment paradigm result in similar outcomes?”  Gynecologic Oncology 2009; 112:337-341.

  • Moore KN. Alward EK, Frank SG, Landrum LM. Myers TK et al.  Adjuvant chemotherapy for the “oldest old” ovarian cancer patients: can we anticipate toxicity related treatment failure in a vulnerable population? Cancer 2009; 115: 1472-1480 and Cancer 23 February 2009

  • Landrum LM, Gold MA, Moore KN, Myers TK, McMeekin DS, Walker JL. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecologic Oncology 2008; 108: 342-347.

  • Moore KN, Reid MS, Fong DN, Myers TK, Landrum LM, Moxley KM, Walker JL, McMeekin DS, Mannel RS.  Ovarian cancer in the octogenarian:  Does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?  Gynecology Oncology 2008; 110(2):133-139.

  • Myers TKN. McMeekin DS. Endometrial Cancer. Conn’s Current Therapy 2007/2008

 
Back